IOL Chemicals (IOLCP)

FairStock Score: 54/100 — MIXED

Score breakdown: P/E: 2/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At first glance, IOL Chemicals offers what looks like a recovering pharmaceutical story. Sales grew 10.91%, profits jumped 40.88%, and the PEG ratio of 0.66 tempts a value hunter. But I must resist the lure of a single ratio. The business earns only 7.00% on equity and 8.86% on capital employed. That is not the kind of return a wonderful franchise produces. In my world, a company's moat shows up in consistently high returns on capital. These numbers tell me IOL operates in a competitive, likely commoditized space where pricing power is limited. The latest quarter reinforces this: ₹580 Cr sales produced only ₹21 Cr net profit, a margin of about 3.6%. That is thin. Financially, the company is conservative: debt/equity is just 0.09, and the Piotroski F-Score of 7/9 suggests the balance sheet is improving. Promoters own 52.62%, so interests are aligned. Dividend yield is 1.37%, modest. However, at ₹92.61, I am paying 17.22 times earnings and 1.65 times book value for a business earning modest returns. That is not a margin of safety. The share sits far below its 52-week high of ₹179.65, but a falling stock price alone is not a reason to buy. I need the underlying earnings power to justify the price. The 40.88% profit growth lifts hope, but with ROE at 7%, the base was low. I would classify this as a turnaround candidate, not a stalwart. I will wait until I see ROE move sustainably higher and margins widen before calling it a great business. For now, it is a perhaps, not a conviction buy.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer